What we do: HIV & AIDS. United nations population fund East and Southern Africa Regional Office (UNFPA ESARO). https://esaro.unfpa.org/en/topics/hiv-aids. Accessed 28 Mar 2023.

Parker E, Judge MA, Macete E, Nhampossa T, Dorward J, Langa DC, et al. HIV infection in Eastern and Southern Africa: highest burden, largest challenges, greatest potential. South Afr J HIV Med. 2021;22(1):1237.

Article  PubMed  Google Scholar 

Miles to Go - The Response to HIV in Eastern and Southern Africa. Global AIDS Update. 2018. https://www.unaids.org/sites/default/files/media_asset/miles-to-go_eastern-and-southern-africa_en.pdf. Accessed 5 Oct 2023.

Heffron R, Ngure K, Odoyo J, Bulya N, Tindimwebwa E, Hong T, et al. Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. Gates Open Res. 2017;1:3.

Article  PubMed  Google Scholar 

Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr. 2013;63 Suppl 2(0 2):S122-9.

Article  PubMed  Google Scholar 

Cambou MC, Landovitz RJ. Challenges and opportunities for preexposure prophylaxis. Top Antivir Med. 2021;29(4):399–406.

PubMed  PubMed Central  Google Scholar 

FDA approves first drug for reducing the risk of sexually acquired HIV infection. US Food and Drug Administration News & Events. 2012. https://www.hiv.gov/blog/fda-approves-first-drug-for-reducing-the-risk-of-sexuallyacquired-hiv-infection. Accessed 11 Mar 2022.

Pre-exposure prophylaxis (PrEP). In Global HIV Programme. World Health Organization. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/prevention/pre-exposure-prophylaxis. Accessed 28 Mar 2023.

Registrar of Medicines, Medicines Control Council.  Medicines control council approves fixed-dose combination of tenofovir disoproxyl fumarate and emtricitabine for pre-exposure prophylaxis of HIV. Medicines Control Council. 2015. https://www.sahpra.org.za/wp-content/uploads/2020/01/6614b94510.11_Media_release_ARV_FDC_PrEP_Nov15_v1.pdf. Accessed 28 Mar 2023.

Masyuko S, Mukui I, Njathi O, Kimani M, Oluoch P, Wamicwe J, et al. Pre-exposure prophylaxis rollout in a national public sector program: the Kenyan case study. Sex Health. 2018;15(6):578–86.

Article  PubMed  PubMed Central  Google Scholar 

Irungu EM, Baeten JM. PrEP rollout in Africa: status and opportunity. Nat Med. 2020;26:655.

Article  PubMed  CAS  Google Scholar 

European Medicines Agency (EMA) approval of the dapivirine ring for HIV prevention for women in high HIV burden settings. 2020. https://www.who.int/news-room/detail/24-07-2020-european-medicines-agency-(ema)-approval-of-the-dapivirine-ring-for-hiv-prevention-for-women-in-high-hiv-burden-settings. Accessed 23 Aug 2020.

WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. World Health Organization. 2021. https://www.who.int/news/item/26-01-2021-who-recommends-the-dapivirine-vaginal-ring-as-a-new-choice-for-hiv-prevention-for-women-at-substantial-risk-of-hiv-infection#:~:text=WHO%20today%20recommended%20that%20the,the%20risk%20of%20HIV%20infection. Accessed 12 Mar 2021.

South Africa approves dapivirine vaginal ring for use by women. International Partnership for Microbicides. 2022. https://www.ipmglobal.org/content/south-africa-approves-dapivirine-vaginal-ring-use-women#:~:text=(March%2011%2C%202022)%E2%80%94,to%20reduce%20their%20HIV%20risk. Accessed 04 Apr 2022.

Gwarisa, M. Dapivirine Vaginal Ring approved for use in Zimbabwe. Health Times. 2021. https://healthtimes.co.zw/2021/07/14/breaking-dapivirine-vaginal-ring-approved-for-use-in-zimbabwe/. Accessed 11 Mar 2022.

Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595–608.

Article  PubMed  PubMed Central  CAS  Google Scholar 

HPTN 084 study demonstrates superiority of CAB LA to Oral TDF/FTC for the prevention of HIV. HIV Prevention Trials Network. 2020. Available: https://www.hptn.org/news-and-events/press-releases/hptn-084-study-demonstrates-superiority-of-cab-la-to-oral-tdfftc-for. Accessed 07 Mar 2022.

FDA approves first injectable treatment for HIV pre-exposure prevention. US Food and Drug Administration. 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention. Accessed 16 Mar 2022.

Zimbabwe is the first country in Africa to announce regulatory approval for long-acting injectable cabotegravir for HIV prevention. World Health Organization. 2022. https://www.who.int/news/item/01-11-2022-zimbabwe-first-country-in-africa-announced-regulatory-approval-for-long-acting-injectable-cabotegravir-for-hiv-prevention#:~:text=Zimbabwe%20is%20the%20first%20country,injectable%20cabotegravir%20for%20HIV%20prevention. Accessed 28 Mar 2023.

SAHPRA registers new long-acting HIV pre-exposure prophylaxis. South African Health Products Regulatory Authority. 2022. https://www.sahpra.org.za/wp-content/uploads/2022/12/MEDIA-RELEASE-New-HIV-HIV-pre-exposure-prophylaxis-2-Dec-2022.pdf. Accessed 28 Mar 2023.

Machado DM, de Sant’ Anna Carvalho AM, Riera R. Adolescent pre-exposure prophylaxis for HIV prevention: current perspectives. Adolesc Health Med Ther. 2017;8:137–48.

PubMed  PubMed Central  Google Scholar 

The HERStory series: lessons learned from implementing a PrEP programme for adolescent girls and young women in South Africa. South African Medical Research Council. 2022. https://www.samrc.ac.za/sites/default/files/attachments/2022-08-18/HSRUPrepBrief.pdf. Accessed 27 Aug 2022.

Palanee-Phillips T, Rees HV, Heller KB, Ahmed K, Batting J, Beesham I, et al. High HIV incidence among young women in South Africa: data from a large prospective study. PLoS one. 2022;17(6):e0269317.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lewis L, Kharsany ABM, Humphries H, Maughan-Brown B, Beckett S, Govender K, et al. HIV incidence and associated risk factors in adolescent girls and young women in South Africa: a population-based cohort study. PLoS one. 2022;17(12):e0279289.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yi TJ, Shannon B, Prodger J, McKinnon L, Kaul R. Genital immunology and HIV susceptibility in young women. Am J Reprod Immunol (New York, NY : 1989). 2013;69 Suppl 1:74–9.

Article  Google Scholar 

Mugwanya KK, Pintye J, Kinuthia J, Abuna F, Lagat H, Begnel ER, et al. Integrating preexposure prophylaxis delivery in routine family planning clinics: a feasibility programmatic evaluation in Kenya. PLoS Med. 2019;16(9):e1002885.

Article  PubMed  PubMed Central  Google Scholar 

Rousseau E, Katz AWK, O’Rourke S, Bekker LG, Delany-Moretlwe S, Bukusi E, et al. Adolescent girls and young women’s PrEP-user journey during an implementation science study in South Africa and Kenya. PLoS one. 2021;16(10):e0258542.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Govender E, Mansoor L, MacQueen K, Abdool KQ. Secrecy, empowerment and protection: positioning PrEP in KwaZulu-Natal, South Africa. Cult Health Sex. 2017;19(11):1268–85.

Article  PubMed  Google Scholar 

Dunbar MS, Kripke K, Haberer J, Castor D, Dalal S, Mukoma W, et al. Understanding and measuring uptake and coverage of oral pre-exposure prophylaxis delivery among adolescent girls and young women in sub-Saharan Africa. Sex Health. 2018;15(6):513–21.

Article  PubMed  PubMed Central  Google Scholar 

de Dieu TJ, Zangeneh SZ, Appelmans E, Pasalar S, Mori K, Peng L, et al. Persistence of oral pre-exposure prophylaxis (PrEP) among adolescent girls and young women initiating PrEP for HIV prevention in Kenya. AIDS Care. 2021;33(6):712–20.

Article  Google Scholar 

Barnabee G, O’Bryan G, Ndeikemona L, Billah I, Silas L, Morgan KL, et al. Improving HIV pre-exposure prophylaxis persistence among adolescent girls and young women: insights from a mixed-methods evaluation of community, hybrid, and facility service delivery models in Namibia. Front Reprod Health. 2022;4:1048702.

Article  PubMed  PubMed Central  Google Scholar 

Rao A, Lesko C, Mhlophe H, Rucinski K, McIngana M, Pretorius A, et al. Longitudinal patterns of initiation, persistence, and cycling on preexposure prophylaxis among female sex workers and adolescent girls and young women in South Africa. AIDS. 2023;37(6):977–86.

Article  PubMed  Google Scholar 

Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: results from HPTN 082, a randomized controlled trial. PLoS Med. 2021;18(6):e1003670.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Haberer JE, Bukusi EA, Mugo NR, Pyra M, Kiptinness C, Oware K, et al. Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial. Lancet HIV. 2021;8(3):e130–7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Haberer JE, Mugo N, Bukusi EA, Ngure K, Kiptinness C, Oware K, et al. Understanding pre-exposure prophylaxis adherence in young women in Kenya. J Acquir Immune Defic Syndr. 2022;89(3):251–60.

Article  PubMed  Google Scholar 

Celum CL, Bukusi EA, Bekker LG, Delany-Moretlwe S, Kidoguchi L, Omollo V, et al. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project. J Int AIDS Soc. 2022;25(7):e25962.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Haberer JE, Bangsberg DR, Baeten JM, Curran K, Koechlin F, Amico KR, et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS. 2015;29(11):1277–85.

Article  PubMed  Google Scholar 

Gilbert HN, Wyatt MA, Pisarski EE, Muwonge TR, Heffron R, Katabira ET, et al. PrEP discontinuation and prevention-effective adherence: experiences of PrEP users in Ugandan HIV serodiscordant couples. J Acquir Immune Defic Syndr. 2019;82(3):265–74.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Myers JE, Sepkowitz KA. A pill for HIV prevention: déjà vu all over again? Clin Infect Dis : Off Publ Infect Dis Soc Am. 2013;56(11):1604–12.

Article  CAS  Google Scholar 

Rutstein SE, Smith DK, Dalal S, Baggaley RC, Cohen MS. Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies. Lancet HIV. 2020;7(10):e721–30.

Article  PubMed  PubMed Central  Google Scholar 

Pintye J, O’Malley G, Kinuthia J, Abuna F, Escudero JN, Mugambi M, et al. Influences on early discontinuation and persistence of daily oral PrEP use among Kenyan adolescent girls and young women: a qualitative evaluation from a PrEP implementation program. J Acquir Immune Defic Syndr. 2021;86(4):e83–9.

Article  PubMed  PubMed Central  Google Scholar 

Camlin CS, Koss CA, Getahun M, Owino L, Itiakorit H, Akatukwasa C, et al. Understanding demand for PrEP and early experiences of PrEP use among young adults in rural Kenya and Uganda: a qualitative study. AIDS Behav. 2020;24(7):2149–62.

Article  PubMed  PubMed Central  Google Scholar 

Ohiomoba RO, Owuor PM, Orero W, Were I, Sawo F, Ezema A, et al. Pre-exposure prophylaxis (PrEP) initiation and retention among young Kenyan Women. AIDS Behav. 2022;26(7):2376–86.

Article  PubMed  Google Scholar 

Velloza J, Khoza N, Scorgie F, Chitukuta M, Mutero P, Mutiti K, et al. The influence of HIV-related stigma on PrEP disclosure and